Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer

Original Article

S.M. Tolaney, E.d. Azambuja, K. Kalinsky, S. Loi, S.-B. Kim, C. Yam, B. Rapoport, S.-A. Im, B. Pistilli, W. Mchayleh, D.W. Cescon, J. Watanabe, M.A.L. Bañuelas, R. Freitas-Junior, J.S. Bofill, M. Afshari, D. Gary, L. Wang, C. Lai, and P. Schmid

N Engl J Med 2026;394:354-366

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Course opens: 
01/21/2026
Course expires: 
01/22/2028

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Please sign in or create an account to take the course.